Some Investors May Be Willing To Look Past LifeTech Scientific's (HKG:1302) Soft Earnings
Some Investors May Be Willing To Look Past LifeTech Scientific's (HKG:1302) Soft Earnings
The market for LifeTech Scientific Corporation's (HKG:1302) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.
最近,生命科技科學公司(HKG:1302)的股票市場並未因弱勢盈利而有太大波動。我們認爲,較軟的主要數字可能被一些積極的潛在因素所抵消。

How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
To properly understand LifeTech Scientific's profit results, we need to consider the CN¥139m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. LifeTech Scientific took a rather significant hit from unusual items in the year to June 2024. As a result, we can surmise that the unusual items made its statutory profit significantly weaker than it would otherwise be.
要正確理解生命科技科學公司的盈利結果,我們需要考慮到飛凡項所產生的人民幣13900萬的開支。看到飛凡項影響公司盈利並不令人愉快,但好的是,情況可能會比想象中更快好轉。當我們分析世界範圍內絕大多數上市公司時,發現重要的飛凡項通常不會重複發生。而且,歸根結底,這正是會計術語的含義。生命科技科學公司在2024年6月的財年中受到了飛凡項的相當大損失。因此,我們可以推斷,飛凡項使其法定利潤明顯較之原本更爲疲軟。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On LifeTech Scientific's Profit Performance
我們對生命科技科學公司的盈利表現看法
As we mentioned previously, the LifeTech Scientific's profit was hampered by unusual items in the last year. Based on this observation, we consider it possible that LifeTech Scientific's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you want to do dive deeper into LifeTech Scientific, you'd also look into what risks it is currently facing. Every company has risks, and we've spotted 3 warning signs for LifeTech Scientific you should know about.
正如我們之前提到的,飛凡在過去的一年中的利潤受到了一些異常因素的影響。根據這一觀察,我們認爲飛凡的法定利潤實際上低估了其盈利潛力!另一方面,飛凡的每股收益在過去的十二個月中實際上有所下降。總而言之,如果您想正確地了解這家公司,就必須考慮更多因素。如果您想深入了解飛凡科技公司,您還需要了解其目前面臨的風險。每個公司都有風險,我們已經發現了3個警示信號,您應該了解一下。
This note has only looked at a single factor that sheds light on the nature of LifeTech Scientific's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
這篇筆記只關注了揭示飛凡科技公司盈利性質的一個因素。但是還有很多其他方法可以了解一家公司的情況。例如,很多人認爲股本回報率高是有利的商業經濟指標,而其他人則喜歡「追蹤資金」並尋找內部人員正在購買的股票。因此,您可能希望查看這個免費收集股本回報率高的公司列表,或者這個高內部持股的股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。